metaPreg - Vigabatrin (All indications) during pregnancy

Vigabatrin (All indications) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	6.04 [1.59, 23.00]	0%	5 studies	49,624	21	not evaluable	ROB	11.56 [2.55; .]
Major congenital malformations	6.04 [1.59, 23.00]	0%	5 studies	49,624	21	not evaluable	ROB	11.56 [2.55; .]
Limb defects	23.44 [1.00, 547.07]	-	1 study	2	6	not evaluable	ROB	46.37 [1.07; .]
Neural Tube Defects	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
Oro-facial clefts	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study